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Abstract
Preimplantation genetic testing (PGT) is widely adopted to select embryos with
normal ploidy but requires invasive embryo biopsy procedures. Therefore, non-
invasive PGT (niPGT) detection of cell-free DNA (cfDNA) in blastocyst culture
medium has gradually become a hot area in the field of assisted reproduction. This
chapter will systematically summarize how researchers use embryonic cfDNA to
conduct niPGT detection worldwide. It will also thoroughly review the factors that
affect the accuracy of the test and its underlying issues, as well as prospective
applications. We hope to provide a useful reference for the standardized operation
of non-invasive PGT that can be widely applied in clinical practice.
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1. Introduction
In vitro fertilization and embryo transfer (IVF-ET) is an effective method for
the treatment of infertility, yet it still has a relatively low success rate [1]. Further-
more, the multiple pregnancy rate remains high as a result of multiple embryos
being transferred, which can increase the chances of adverse pregnancy outcomes
and affect the health of both the mother and children [2]. Elective single embryo
transfer (eSET) is the most effective way to reduce the rate of multiple pregnancies
and is increasingly used worldwide [3]. Nonetheless, the success rate of single
embryo transplantation is not satisfactory, mainly due to the lack of a systematic
approach for evaluating the conceivability of embryonic development. Presently,
embryonic morphological assessment is still the most commonly used method, but
this method has many problems due to the lack of quantifiable indicators and its
susceptibility to subjective factors of laboratory embryologist [4–6].
Studies have shown that there is an approximately 40%–60% risk of chromo-
somal aneuploidy even before embryo implantation [7–9]. PGT-A can be used to
identify embryos with chromosomal aneuploidy, thereby improving clinical out-
comes in IVF patients [10–13]. Nonetheless, PGT-A relies on embryo biopsy, and its
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invasive biopsy approaches may increase its technical limitations for the following
reasons: (1) it may have an influence on the quality and the level of development of
the embryo [14]; (2) it may increase the chance of abnormal epigenetic modifica-
tions [15, 16]; (3) it has high requirements on the environment and operating
instruments, and there is a potential risk of sampling failure; and (4) the accuracy
of test results may be affected by mosaicism. Consequently, it is necessary to
establish an optimal selection procedure in line with the morphological assessment
for embryos that truly reflects the chromosome ploidy status of the embryo, avoids
invasive operations, and does not require expensive equipment. Recently, several
studies have found the presence of cfDNA in the culture medium and blastocyst
fluid of embryos [17–21]. Noninvasive PGT-A detection through cfDNA has
become a growing niche in the field of assisted reproduction. In this chapter, we will
comprehensively review the advancements and attempts at noninvasive PGT-A
using foetal cfDNA and discuss the pros and cons as well as insights into its clinical
applications in IVF-ET.
2. cfDNA research based on Spent culture media (SCM)
2.1 The discovery of cfDNA in SCM
Stigliani et al. [18] first demonstrated the presence of cfDNA in SCM in 2013,
where genomic DNA (gDNA) was found in 63% (205/326) of the 326 SCMs col-
lected, ranging from 41 pg to 1.8 ng. Subsequently, Hammond et al. [19] also
detected mitochondrial DNA (mtDNA) and gDNA in SCMs. In addition, Stigliani
et al. [22] reported that the ratio of mtDNA to gDNA in the SCM of D3 was
positively correlated with the formation rate of blastocysts. These results suggest
that SCM can serve as a sampling source for early embryonic DNA, laying the
foundation for the development of the non-invasive method of PGT-A.
2.2 Application of SCM in PGT-A
In recent years, an increasing number of studies have been conducted to evalu-
ate the feasibility of SCM-based non-invasive PGT-A approaches, and some of the
results are encouraging. Many studies have found that PGT-A by trophectoderm
(TE) biopsy or whole embryo of SCM has a high consistency rate (as shown in
Table 1. Pro). Nevertheless, other research groups have reported relatively low
consistency rates when compared with TE or whole embryo results (see Table 1.
Con). These contradictory results may be related to factors such as the
difference in SCM sampling methods and sampling time used in the studies, embryo
treatment, and the definition of consistency. By improving the detection method,
non-invasive PGT-A using SCM is expected to meet the requirements of clinical
diagnosis.
2.3 Factors affecting the accuracy of non-invasive PGT-A
When comparing the ploidy consistency of cfDNA in SCM, all studies have
reported a high success rate of cfDNA amplification and detection, ranging from
77.3% to 100% (as shown in Figure 1). However, its consistency to the conventional
PGT-A results fluctuated widely, ranging from 33% to 100% [23, 26, 27, 39] (as
shown in Figure 2). Hence, it is critical to recognise the factors influencing
accuracy.
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ICSI Single medium Yes D5/D6 embryo (freeze-thaw):
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ICSI Single medium No D4 D6/D7 (Fresh):
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2.3.1 Influence of sampling time on accuracy
At present, there are two common types of commercial embryo culture systems:
sequential culture and single culture systems. However, the quality of DNA in SCM
degrades as a result of cfDNA degradation over time. Therefore, the time and
opportunity for cfDNA degradation could be minimized via media changes. Addi-
tionally, the maternal DNA contamination introduced by residual cumulus cells
could be reduced or eliminated by media change to a certain extent. The results of a
few studies using a single culture system [36–38] and sequential culture medium
[31, 39, 41] are listed in Table 1. Importantly, Rubio et al. showed no significant
Figure 1.
Success rates of WGA amplification and CNV detection reported in different niPGT studies.
Figure 2.
CNV concordance rate reported in studies comparing SCM with TE or whole embryo samples.
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difference in the influence of different culture systems on consistency when
performing the same sampling process [29] (as shown in Figure 3).
As the fertilized egg develops, DNA is constantly released into the SCM, which is a
dynamic process. The test results of SCM collected at different time points during
embryo culture may vary. Using a single medium, Ho et al. [37] achieved detection
success rates of 39% (16/41) and 80.4% (33/41) when SCMswere collected on D3 and
D5, respectively. When comparing the SCM collected on D3-D5 and D4-D5, Lane
et al. [43] found that the accuracy was higher in later samples, with >95% ploidy
consistency and 100% consistency of the sex chromosome. The primary explanation
for these observations may be that the number of embryonic cells increases exponen-
tially with in line with embryonic development and that the concentration of cfDNA
surges dramatically at later stages of the development. Rubio et al. [28] transferred
embryos into new culture drops onD4 and collected SCM on D5 to D7. The SCM
consistency of D4-D6/7 was significantly higher than that of D4-D5 (84.0% vs.
63.0%), and the level of maternal contamination was also reduced. A multicentre
clinical study which supports the above assumption. conducted by the same team that
compared SCM and TE samples using a large sample size of 1,301 embryos, also
achieved a remarkable 78.2% (866/1108) concordance rate using D4-D6/7 SCM sam-
ples [29].While the consistency rate jumped to 92.0% if the culture were last until D6.
The above studies have shown that to maximize the collection of cfDNA content
and ensure the detection rate and accuracy of cfDNA, there is an optimal collection
time for SCM on the premise of ensuring the blastocyst rate and excellent embryo
rate. For the fresh ET cycle, D4 to the pre-cryopreservation blastocyst stage
(D5/D6/D7) could be the optimal collection time. Several studies of ni-PGTA have
also been conducted on frozen-thaw embryos, where the culture media were col-
lected at later stages and the assay performance was slightly better compared to that
of the fresh embryos (as shown in Figure 4).
2.3.2 Fresh-frozen embryos yield better niPGT performance than fresh embryos
In cryopreservation of embryos, assisted blastocyst shrinkage is usually
performed during vitrification of the embryo. Shrinkage of the blastocyst cavity
before vitrification can prevent the formation of ice crystals and improve the
survival rate of embryos after cryopreservation [44]. This process leads to lysis of
cell membrane, which increases the likelihood of that embryonic cells releasing
cytoplasmic materials, including genomic DNA, into the SCM, thereby increasing
Figure 3.
CNV concordance rates of SCM versus TE biopsies in using different brands of culture media. No statistical
differences were observed in four major brands of media. Data from Rubio et al. [42] (Ref). Data from Rubio
et al. Embryonic cell-free DNA released to the spent blastocyst media. Am J Obstet Gynecol 2020.
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the concentration of DNA templates available for the downstream whole genome
amplification (WGA) of niPGT-A. Furthermore, the vitrification process may lead
to a higher rate of cell apoptosis, which also potentially increases the amount of
cfDNA in the media after thawing and recovery. Kuznyetsov et al. [23] compared
the amplification outcomes of a mixture of SCM and blastocyst fluid collected
before vitrification (19) and after vitrification (30). The average amount of DNA
obtained from fresh embryo culture amplification (6.3 ng/μL 36.0 ng/μL) was
lower than that obtained from vitrification-revival blastocysts (10.5 ng/μL
44.0 ng/μL). After thawing 52 donated frozen blastocysts with TE biopsy results,
Huang et al. [24] found that 48 of them (92.3%) were successfully amplified, and
the data could be used for the analysis, with a consistency of 93.8% (45/48) to the
whole embryo results. Jiao et al. [25] assessed 41 frozen blastocysts donated by 22
couples with known chromosomal rearrangements and 21 frozen blastocysts
donated by 8 couples with normal karyotypes for PGT-SR and PGT-A analysis,
respectively. All BCM (a mixture of SCM and BF) samples (62/62, 100%) were
amplified successfully, and the clinical consistency between the niPGT-A results
and the whole embryo was 90.48% (19/21). For PGT-SR results, the clinical consis-
tency of BCM in chromosomal rearrangement and its corresponding whole embryo
sample was 100% (41/41). Li et al. [26], using similar sampling methods, assessed
41 embryos and 97.6% were successfully amplified, and the clinical consistency
between the niPGT-A results and the whole embryo was 87.2%. In summary, the
SCM of cryopreserved-and-thawed embryos may contain more cfDNA than fresh
embryos, which would minimize amplification failures and improve the reliability
of the test results. This finding may be beneficial for patients who have had mis-
carriages due to embryo chromosomal abnormalities in the previous ART cycle.
Providing that patients have sufficient cryopreserved embryos, they may take
advantage of niPGT-A to screen euploid embryos for transplantation prior to the
next transplantation cycle with resuscitated media (as shown in Figure 4).
2.3.3 Methods of whole-genome amplification
Given the challenge of low-concentration cfDNA in SCM, a WGA method with
high uniformity and fidelity is required to amplify a small amount of genetic
Figure 4.
Comparing SCM collection strategies and its impact on CNV concordance rate.
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material to accurately detect the genetic status of embryos. Different WGA tech-
niques discussed in the chapter include multiple displacement amplification
(MDA), multiple annealing and looping-based amplification cycles (MALBA) and
Sureplex/Picoplex (as shown in Figure 5).
MALBAC has a unique characteristic similar to linear amplification, which can
reduce the sequence-dependent bias exacerbated by exponential amplification [34].
Several niPGT-A studies have used MALBAC to amplify cfDNA in SCM, and the
success rates ranged from 90.9% to 100% [24, 31, 35, 38]. In 2019, Jiao et al.
developed NICS-INST technology based on MALBAC, which incorporated WGA
and library preparation in the same amplification step, achieving a 100% (41/41)
detection rate in SCM [25].
Picoplex/Sureplex is currently the most widely used WGA methods for conven-
tional PGT-A. One study used Picoplex for SCM amplification with a success rate of
97% [37]. In another study using the Sureplex amplification method, the amplifica-
tion rate of 22 SCM samples reached 81.8%, and all the amplified samples produced
PGT-A results by aCGH [36]. A study using Sureplex WGA in combination with
blastocyst fluid (BF) and SCM found amplification rates of 100% in 28 samples, all
of which produced PGT-A results [23]. In one SCM study with a large sample size of
168, 89.3% of the samples were successfully amplified by Sureplex, and 77.3% of the
sequenced samples yielded PGT-A results [34]. Lledo et al. compared Veriseq
(Illumina®) and NICS (Yikon®), which both achieved 92.4% amplification success
rates. The consistency of the culture medium collected on D6 and TE biopsy was
92.0% and 86.5%, respectively [30].
MDA is an isothermal amplification reaction using Phi29 DNA polymerase [45].
Amplification bias due to nonlinear amplification remains a significant fault in the
technique. Studies using MDA on SCM have shown an amplification success rate of
97%; however, only 2% of the amplified samples produced reliable PGT-A results
[39]. Since the cfDNA of SCM is dominated by short fragments with a length of
160–220 bp [46], this would especially affect the MDA-based method, which
requires longer DNA fragments to achieve optimal amplification.
The Phi29DNA polymerase used in MDA technology has high fidelity but is
restricted by the starting amount of the DNA template. When the starting amount is
very low, the coverage rate and accuracy of the amplified products can decrease
Figure 5.
Comparing SCM amplification methods and the concordance of CNV in different study MALBAC and
SurePlex, PicoPLEX and IonReproseq are the main methods, MDA is not applicable.
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dramatically. Malbac and Sureplex have the advantages of high genome coverage,
low ADO rate, and a low number of starting DNA templates required. However,
DNA polymerase has lower fidelity than Phi29 polymerase, which leads to an
increased false positive rate compared to MDA.
2.3.4 Standard of the mosaic threshold of embryo
Embryonic mosaicism refers to the existence of two or more cell lines with
different genotypes in the same embryo. Some studies suggest that abnormal cells in
a mosaic embryo are gradually diminished, i.e., a certain degree of self-repair occurs
during embryonic development [47–49]. Mosaic embryos, especially those with a
low proportion, still have a decent success rate of pregnancy after being implanted
[50, 51]. Therefore, there is a trend of accepting low-frequency mosaic embryos in
clinical practice.
Chromosome ploidy of mosaic embryos can be quantified by the proportion of
mosaics (M), and samples with results above a certain threshold of M are identified
as aneuploidy embryos. Therefore, the proportion of false positives and false nega-
tives in embryo chromosome detection relies on the threshold setting of M. We
observed that different studies had different criteria for reporting mosaicism, rang-
ing from 30% to 60%. Yeung et al. [34] set the minimum threshold as 30% and
recommend against the implantation of mosaic embryos >30%. Bolton et al. [47]
found that the elimination of aneuploidy cells in the ICM through apoptosis may
result in an increase in aneuploidy fragments in the SCM. Thus, increasing the
chimaerism threshold of SCM samples may reduce the false positive rate and
improve the consistency rate. In the study of Jiao et al., samples with a mosaic ratio
of less than 40% were defined as euploid, while samples with ≥40% were defined as
aneuploid [25]. Rubio et al.’s study directly defined samples with a chimaerism ratio
of <50% as euploidy and ≥ 50% as aneuploidy, and no mosaic embryos were
reported [28]. Huang et al. observed that using 60% as the threshold for
distinguishing aneuploidy from euploid embryos achieved a false negative rate of
zero, significantly improving the results of non-invasive PGT-A [24]. This study
suggests that appropriately increasing the aneuploidy threshold can minimize the
mosaic false positives caused by NGS results to a certain extent; however, these
adjustments would require validation on a much larger scale.
2.3.5 Whole embryo samples are more suitable as the gold standard for niPGT evaluation
Individual research groups may use different gold standards when evaluating
the accuracy of SCM or BF detection results. At present, TE biopsy is the standard
clinical practice for PGT-A; thus, TE biopsy is often used as the gold standard.
However, due to the presence of chimaeric embryos, studies have questioned
whether a couple of TE biopsy cells is able to accurately represent the ploidy of the
inner cell masses. There was also a study performed to compare the ploidy results
from cfDNA and polar body biopsy [36]. Although the polar body is naturally
released from oocytes, which are minimally invasive, it only examines aneuploidy
of maternal meiosis origin and is limited by its inability to directly evaluate the
genetic status of the entire embryo [52].
Consequently, the D5 whole embryo for comparison with cfDNA as the gold
standard may be the most appropriate when considering the accuracy of the given
selected comparison criteria. Several studies have reported the use of the whole
embryo as the gold standard. SCM collected from thawed blastocysts was assessed,
which achieved overall consistency with the WB samples, ranging from 90.48% to
96.4% in all these studies [23–25]. Nevertheless, it can be challenging to obtain
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donated WB, even though it may be the best representation of the genetic status of
the entire embryonic genome.
2.3.6 The determination for concordance
The concordance between the SCM and the selected gold standard, e.g., con-
ventional TE biopsy or whole embryo, can be analysed from several aspects, as
shown in Table 2.
First, the statistics of the consistency rate can be grouped into the following
three situations: (1) the negative consistency rate (euploidy vs. euploidy), that is,
both SCM and gold standard are negative results reported as euploidy, which is also
the most critical indicator in clinical practice. Generally, clinicians choose euploid
embryos for transplantation, and the accuracy of this indicator often directly
impacts the clinical outcome. (2) The positive consistency rate (aneuploidy vs.
aneuploidy), that is, both SCM and gold standard are positive results reported as
aneuploidy. Usually, clinicians would not choose such embryos for transplantation.
Hence, the accuracy will directly affect the availability of embryos for transplanta-
tion and the cycle cancellation rate. (3) The overall consistency, which is a compre-
hensive evaluation including both euploidy and aneuploidy.
Second, the researchers likewise have different ways to calculate consistency.
(1) Clinical consistency refers to the test results for the impact on the clinical
decision, as some researchers suppose that only euploid embryos would be
considered for implantation, which means clinical consistency is the foundation,
which agrees with the transplant decision (as shown in Figure 6). (2) Full
consistency: it can only be considered consistent when the test result is absolutely in
line with the karyotype, especially for patients with known chromosomal
abnormalities (as shown in Figure 6). (3) Partial consistency: Some researchers
consider SCM and the gold standard to be two different types of samples. Thus,
they should be considered as consistent if there is partial consistency with the
karyotypes.
Third, the criteria for the reporting of aneuploidy are not uniform. Researchers
usually consider whether to report fragmentation abnormalities or whole chromo-
some abnormalities and whether to report mosaic results and their reporting
criteria.
Through the analysis of a series of related studies (see Table 2), we observed
that although different investigators used different methods to calculate consis-
tency, the consistency results were superior to other methods when only clinical
consistency rates were considered.
In the studies of Huang et al. [24], Jiao et al. [25], Li et al. [35], Liu et al. [38], and
Yeung et al. [34], when the karyotype was completely consistent or partially con-
sistent, the results’ coincidence rates to the gold standard were 83.3%, 76.2%, 50%,
64.5% and 62.1%, respectively. However, the consistency rates increased to 93.8%,
90.5%, 78.9%, 83.9% and 73.3%, respectively, when only clinical consistency was
considered.
In addition, in the analysis of Kuznyetsov et al., if only chromosomal aneuploidy
was considered, the clinical consistency rate was often better than the results of
fragment abnormalities and consistent karyotypes. The clinical concordance of
frozen embryos and fresh embryos was 96.4% and 100% without considering
chimaerism and fragment abnormalities, respectively, but decreased to 78.5% and
73.7% when considering chimaerism and fragment abnormalities, respectively. In
addition, only euploidy and aneuploidy were distinguished according to the chro-
mosomal test results given, and the positive and negative consistency rates in each
study were calculated.
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In general, the negative consistency rate is better than the positive consistency
rate in SCM, which may indicate high false positives in the niPGT-A test. On the
other hand, it also shows that the negative result of this approach is more reliable. In
summary, the definition of consistency has a direct impact on the final results of the
assessment method. Considering the speciality of cfDNA presented in SCM, it
seems insufficient to define consistency purely based on the perfect match of the
CNV patterns. Chen et al. [27] proposed the embryos can be categorized or scored
by the obtained niPGT-A results into three groups: (A) chromosomal normal, (B)
chromosomal abnormal, and (C) multiple abnormal chromosomes or uncertain.
The results showed group A predicts a normal embryo with 90.0% probability,
while groups B and C predict 27.8% and 72.2% normal probability, respectively.
Thus, it may be necessary to fully consider the conditions, such as mosaicism,
ploidy status and test resolution, when establishing the analytical model.
It seems more appropriate to use whole blastocysts as the gold standard for
evaluation of the accuracy of niPGTA. Apparently, the establishment of the model
would require large embryos of SCM and WB paired samples, with standardized
sample collection and data analysis procedures. Furthermore, the model can evalu-
ate SCM according to the euploidy probability of embryos to obtain the priority or
exclusion order of embryos for implantation to avoid the waste of embryos due to
false-positive decisions led by conventional PGT-A.
2.4 Clinical application of non-invasive PGT-A
At present, several studies have applied non-invasive PGT-A to diverse patient
groups to preliminarily evaluate the clinical manifestations of the technique. Xu
et al. [31] used non-invasive PGT-A for the first time in balanced translocation
patients and obtained five live births from seven couples. Rubio et al. [28] com-
pared the clinical outcomes of two groups of patients, one with both TE biopsy and
SCM results of euploidy and the other with TE biopsy negative and SCM results of
aneuploidy. The transplant success rate of patients with both euploidy TE and SCM
results was twofold (52.9% vs. 16.7%) higher than that of the latter group. Zero
miscarriages were observed (0/9) when both the TE and SCM results indicated that
Figure 6.
Definition of concordance between SCM and the gold standard are at different levels in studies. Yeung et al.
defines concordance at chromosome level, while Rubio et al. defines at the level of clinical concordance.
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the embryos were euploid. Moreover, Fang et al. [53] reported the results of a
single-centre clinical trial in 2019 applying non-invasive PGT-A on patient groups
with either repeated implant failures (≥3) or repeated miscarriages (≥3). The trial
included 45 couples with 50 ART cycles, resulting in a biochemical pregnancy rate
of 72% (36/50), a clinical pregnancy rate of 58% (29/50), and a spontaneous mis-
carriage rate of 10% (3/29), with a total of 27 babies successfully delivered. While
the clinical trial scale of the above studies was small, the cfDNA-based niPGT-A
proved in principle that it could reduce miscarriage and improve the ongoing
pregnancy rate. Conversely, large-scale randomized controlled clinical trials are
needed to conclude whether non-invasive PGT-A can be an effective way to evalu-
ate embryo implantation potential.
3. Studies of cfDNA in blastocyst fluid (BF)
3.1 Presence of cfDNA in in blastocyst fluid (BF)
The presence of cfDNA in blastocyst fluid (BF) was revealed as early as 2013.
For the first time, Palini et al. [17] reported that genomic DNA has identified in 90%
(26/29) BF by qPCR, with an average amount of gDNA at 9.9 pg. TBC1D3 on chr17
and TSPY1Y on the Y chromosome were successfully amplified, which confirmed
that the sex of embryos could be determined by qPCR using BF. In addition,
genome-wide amplification (WGA) was demonstrated for blastocyst fluid amplifi-
cation, and aneuploidy detection of WGA products was performed using microar-
ray comparative genomic hybridization (aCGH). The aCGH results revealed the
presence of the Y chromosome in two BF samples, which was consistent with
previous data obtained by PCR analysis. It also showed multiple chromosomal
abnormalities that agreed with the karyotype, suggesting that the WGA product
DNA was indeed of embryonic origin. Subsequently, Zhang et al. [46] performed
next-generation sequencing on WGA-amplified BF DNAs and compared the data
with paired blastomere biopsy samples. The results showed decent concordance in
genomic coverage and pattern regions between the two DNA sources. Further
analysis of the gene annotation results suggested that cfDNA in the BF contained
the sequences of the majority of genes, indicating that cfDNA in the BF could be
used for solving monogenic diseases.
3.2 Sampling method of blastocyst fluid
BF can be isolated from embryos for downstream analysis using blastocyst
puncture, which is a microscopy-assisted puncture made with an ICSI injection
pipette on the trophoblast side, opposite of the inner cell mass. The fluid is then
taken until the blastocyst completely collapses around the pipette [54]. This method
can only isolate minute amounts (0.01 μL) of BF for analysis [55, 56].
3.3 Study of PGT-A using blastocyst fluid
Recently, BF has been studied as a source for minimally invasive PGT-A. In
2014, Gianaroli et al. [57] isolated BF from 51 blastocysts, and the average concen-
tration of WGA-amplified DNA detected in 39 BF samples (76.5%) was 900.38 ng/
μL (ranging between 876.3–939.5 ng/μL). The results of BF detected in 38 cases (38/
39, 97.4%) were consistent with the ploidy of TE biopsy results, and 9 cases (9/9,
100%) were consistent with the ploidy of the blastomere biopsy, and the coinci-
dence rate of PB ploidy was 93.3% (28/30). Magli et al. [55] of the same group
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improved the sampling and amplification of BF samples to a success rate of 82%
(95/116). aCGH was performed on 87 of these samples, of which 82 samples (94%)
were used for subsequent analysis. The ploidy consistency of BF and TE samples
was 97.1% (67/69), 94.4% (34/36) with blastomere biopsy and 94.1% (32/34) with
polar body biopsy. In 2019, Magli et al. [12] used the same approach to amplify
blastocyst fluid extracted from 256 blastocysts with a 71% (182/256) WGA amplifi-
cation rate. Compared with the results of the corresponding TE cells, the overall
ploidy consistency was 93.6% (161/172). The above results suggested that the
cfDNA of the BF was highly predictive of embryo ploidy; however, the results from
other research groups have been less satisfactory.
Tobler et al. [58] obtained a WGA amplification success rate of 63% (60/96) after
thawing and culturing donated embryos to extract BF. The concordance between the
BF karyotype and the whole embryo was 48.3% (29/60) by aCGH analysis,
suggesting that BF may not be suitable for the PGT test. In 2018, Tsuiko performed
chromosome analysis using NGS on 16 donated blastocysts, and the success rate of BF
amplification was 87.5% (14/16). However, only 10 samples (10/16, 62.5%) passed
sequencing and quality control for the subsequent analysis. The results showed that
only 40% (4/10) of the BF samples completely agreed with the TE or ICM results. In
addition, significantly more mosaicisms were found in BF samples than in TE and
ICM samples. These results together suggest that although BF-DNA can be success-
fully amplified for NGS, one would not recommend using BF as a single DNA source
for preimplantation genetic screening due to its low concordance with ICM and TE
results. Capalbo et al. [59] (2018) performed PGT-A on 23 BF samples and compared
the results with TE. Only 8 cases (34.8%) were successfully amplified, and only 3
cases (37.5%) were consistent with the ploidy of TE detection results.
In summary, studies assessing the reliability of BF DNA as a template for PGT-A
have yielded conflicting conclusions, with 37.5%–97.4% concordance with TE sam-
ples (Table 3). Differences in consistency levels between studies may be related to
differences in embryo handling. Tsuiko and Tobler used frozen embryos donated by
patients after treatment, and BF was absorbed after blastocyst resuscitation and
expansion; Tobler’s study [58] specifically suggests that they are not suitable for
clinical use. In contrast, the BF samples of Gianaroli, Magli and colleagues were
obtained from fresh culture cycles and underwent many procedures (PB biopsies,
assisted incubation and blastomere biopsies) that were not performed or relatively
few procedures were performed in other studies. Thus, the observed increased rates
of amplification and concordance may be due to the superior quality of BF obtained
from freshly cultured embryos over frozen embryos or to an increase in the amount
of DNA in the blastocyst cavity resulting from unintentional cell lysis or death during
the procedure. It is also important to point out that the sample size in the Capalbo and
Tsuiko studies was much smaller than that of Gianaroli, Magli and colleagues, so
different results might have been obtained if a larger sample size had been studied.
According to the results of available studies collectively, BF DNA presented a
high percentage of DNA amplification failure. The percentage of blastocyst fluid
samples that successfully underwent whole genome amplification and produced
detectable levels of DNA ranged from 34.8% to 82% [46, 58–60]. The difficulty in
the successful amplification of BF-DNA lies in the small amount of fluid obtained
from the cystic cavity, and the BF volume reported in various studies ranged from
0.3 nl to 1 μl. The volume difference would significantly impact the concentration of
BF-DNA and may impose a negative effect on the efficiency of subsequent amplifi-
cation. Another major reason for failure in BF-DNA amplification would be degra-
dation. The success rate of whole genome amplification was generally much higher
(≥98%) [58, 61] in TE biopsy, which makes BF DNA less suitable as an alternative
source for clinical application [19].
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Gianaroli et al. [57] Fresh Blastocentesis D5 1 μL Sureplex 76.5%(39/51) aCGH 100% vs BM(9/9)
97.4% vs TE (38/39)
93.3% vs PB(28/30)
Magli et al. [55] Fresh Blastocentesis D5 0.01 μL SurePlex 82%(95/116) aCGH 94.4% vs BM(34/36)
97.1% vs TE (67/69)
94.1% vs PB(32/34)
Magli et al. [60] Fresh Blastocentesis D5 The aspirated fluid was transferred
into a 1-μL droplet of PBS
SurePlex 71%(182/256) aCGH 93.6% vs TE (161/172)
CON
Tsuiko et al. [56] Cryopreserved
blastocysts
Blastocentesis D5 0.01 μL Picoplex 62.5% (10/16) NGS 40% vs ICM 或TE(4/10)
Tobler et al. [58] Cryopreserved
blastocysts
Blastocentesis D5 1 μL SurePlex 63%(60/96) aCGH 48.3% vs EB(29/60)
Capalbo et al. [59] Fresh Blastocentesis D5 The aspirated fluid was transferred
into a 5-μL droplet of medium
SurePlex 34.8%(8/23) NGS 37.5% vs TE(3/8)
Table 3.












In addition, blastocyst puncture is still a minimally invasive procedure, as an
ICSI needle is inserted into the blastocyst cavity to extract the fluid. However, with
the presence of amplifiable cfDNA in the BF, the low consistency of the test results
to TE or other gold standards suggests that technical variability may still exist. The
process may accidentally acquire loose cells trapped in the lumen or shed cell
material, resulting in inconsistent test outcomes. Thus, further optimization is
required before using BF DNA for PGT.
3.4 Correlation between BF test results and clinical outcomes
The DNA concentration in the BF was very low, and the total amount varied
greatly between samples, implying that the BF DNA amount could be related to the
developmental status of embryos. In 2019, Magli et al. [60] showed a significantly
higher WGA amplification success rate of BF in aneuploid blastocysts (n = 150,
81%) versus euploid blastocysts (n = 32, 45%), suggesting differences in the quality
or total amount of DNA in the BF of euploidy and aneuploidy embryos. Moreover,
the clinical pregnancy rate was 77% in the group with failed BF amplification and
37% in the group with successful BF amplification when following the clinical
outcome of 53 TE euploid blastocysts. The same trend was found in the rate of
persistent pregnancies in failed and successful amplified BF samples, which were
68% and 31.5%, respectively. These clinical results suggest that the success of BF
amplification may have predictive value for the viability of the corresponding
blastocyst; nevertheless, further validation is required to draw conclude. Given that
the total amount of DNA in the BF is relatively low, combining blastocyst fluid and
culture medium may increase the amount of cfDNA, therefore improving the
amplification success rate and consistency of detection.
4. Problems in the application of cfDNA to PGT-A
Before the large-scale use of SCM in PGT-A, further investigations are needed to
trace the origin of cfDNA and confirm whether cfDNA represents the euploidy of
embryos.
4.1 The origin of cfDNA
At present, there are several opinions about the origin of cfDNA. It is believed
that during embryonic development, cfDNA may be released into the culture media
through cell lysis, apoptosis, cell debris or other mechanisms [19]. In apoptotic cells,
DNA is cleaved to form fragments. These fragment sizes are multiples of approxi-
mately 180-bp oligomers [62]. Zhang’s [46] research shows that the fragments have
two peaks. The first peak had a range of 160–220 bp, whereas the second peak was
broader, ranging from 300 to 400 bp. Bolton et al. [63] found that apoptosis was
frequently observed within the ICM and TE between euploid cells and aneuploid
cells in a mouse model. The results also showed that in aneuploid embryos, the
percentages of apoptotic cells in the ICM and TE were 41.4% and 3.3%, respec-
tively. In euploid embryos, the percentage of apoptotic cells in euploid cells was
19.5% and 0.6%, respectively. If cfDNA mainly comes from apoptotic cells, Bolton’s
and other studies demonstrate that cfDNA mainly originates from the ICM.
Moreover, Victor et al. [51] tracked the development of embryos dynamically
using immunofluorescence technology, especially cell proliferation and apoptosis in
euploid embryos, aneuploid embryos and mosaic embryos. The TE and ICM in
euploid cells showed lower level of activities in both not only in cell proliferation
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but also in apoptosis. Nevertheless, in mosaic and aneuploid embryos, the levels of
the two processes were both higher.
4.2 Maternal contamination
The discordant results in SCM and control embryos were mainly attributable to a
high percentage of maternal DNA in the spent culture media. The Vera Rodriguez
team [41] analysed the SCM and TE results from 56 samples. Among them, 17
embryos were detected as aneuploid or aneuploid males (XY) by TE, while all of
them were detected as aneuploid females (XX) by SCM. When Feichtinger et al.
compared the consistency between the SCM and polar body, the negative control
(SCM of fertilization failure oocytes) was also effectively amplified. Oocytes are
unlikely to abandon their DNA to the culture media. Therefore, this maternal
contamination may come from cumulus cells or other exogenous DNA [36]. How-
ever, contamination may be minimized with the degradation of DNA in vitro by
changing the solution in the sequential culture at D3 and delaying the sampling
time. In sequential culture, if the granular cells before ICSI are not removed
entirely, it is recommended to remove them again during the culture medium
change on Day 3.
To reduce the interference of human judgement, we should develop a calcula-
tion method to eliminate maternal DNA for the purpose of internal quality control.
To confirm whether there was maternal DNA contamination in the embryo
medium, Hammond et al. carried out a short tandem repeat (STR) analysis on
abandoned spent culture media (n = 10), media controls (n = 2) and the
corresponding cumulus cells [64]. Maternal DNA from cumulus cells successfully
amplified all gene loci, but the amount of DNA in the SCM was too small to identify
DNA. STR analysis is a long-range amplification, and highly fragmented SCM DNA
seems unsuitable for this detection. Vera Rodriguez et al. conducted SNP sequenc-
ing of three groups of samples (TE/follicular fluid DNA/embryonic SCM DNA)
from 35 embryos and successfully quantified the proportion of maternal DNA
contamination in SCM [41]. This suggests that SNP detection can be used to
evaluate maternal contamination in SCM.
In addition, considering that the fragment size of cfDNA may be different from
that of maternal contamination DNA, or according to the cleavage characteristics of
cfDNA at the restriction site, it can be considered to identify the target fragment size
and restriction site characteristics, and only analyse the DNA that conforms to the
embryonic DNA. The hypothesis is that there is a DNA amplification and database
construction method that can maintain the characteristics of DNA fragments or
restriction sites, and the original cfDNA template can be amplified with high fidelity.
4.3 Background cfDNA contamination of SCM
Some studies have suggested that another source of exogenous DNA contami-
nation is the low level of background DNA in SCM. In 2017, Hammond et al. [64]
detected low baseline levels of DNA in the base media and protein supplement
components of three commercial culture media. They also detected a copy of
nuclear DNA in the culture media with no previous contact with embryos. Vera
Rodriguez et al. [41] detected DNA quantification using qPCR in 53 spent culture
media and 17 control samples (culture media with no previous contact with
embryos). Then, PGT-A analysis was performed in 56 spent culture media and 11
control samples. The SCM was amplified successfully, and 11 controls generated an
amplification-failure pattern, causing downstream analysis failure. In addition, Li
et al. [35] found that the background DNA of the control culture did not interfere
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with the detection results, and all samples from the same embryo had the same sex
chromosome diagnosis. The results testified that although there was a low baseline of
exogenous DNA in the control SCM, the effect could be ignored due to the small
amount of exogenous DNA. In addition, some commercial media use human serum
albumin (HSA) to improve embryo development. Because HSA can adsorb DNA, the
amount that is added should be controlled within a reasonable range. We suggest that
the blank culture medium should be set as the parallel culture at the same time as
recovering blastocyst culture media for quality control of SCM samples.
5. Prospects
Using SCM cfDNA for PGT-A has become a hot topic in the assisted reproductive
field. The current research focuses on the aneuploidy consistency between cfDNA and
embryos. However, the consistency comparison needs to consider many influencing
factors, such as the definition of consistency, samplingmethods, analysis methods, etc.
We need to reach a certain consensus and standard before making an objective evalu-
ation. Through the summary and introduction of this review, we found that a suitable
sampling time, WB as the gold standard, suitable amplification methods and NGS
platforms may provide the basis for the standardization of non-invasive PGT-A.
In the future, we should develop a standardized and automatic embryo culture
and sample collection system based on the operating habits and culture process of
the embryo laboratory. Meanwhile, we need to combine the sample downstream
detection technology with corresponding software analysis to select the best
embryos, which are those with the lowest probability of chromosomal abnormali-
ties, for transplantation to improve the success rate of the whole IVF-ET cycle. It is
believed that with the development of technology, the realization of automatic
collection and detection platforms, the accumulation of detectable sample sizes, and
the average cost of PGT-A detection on each embryo will be greatly reduced, and it
is encouraging that SCM sample collection and detection will be developed into the
routine process of embryo laboratories.
With the accumulation of data, SCM can be used to develop detection content
for different populations. For the low-risk population with chromosomal abnor-
malities, we can give the risk value of chromosomal abnormalities on chromosome
16, which easily causes abortion, and on chromosomes 13, 15, 18, 21 and X, which
easily cause birth defects. Referring to the NIPT method, the influence, caused by a
proportion of false positive cfDNA, will be reduced. For high-risk populations with
chromosomal abnormalities, such as elderly individuals, the consistency between
SCM test results and embryos is high, and the interference of false-positives is
relatively low. For this group of people, it is recommended to conduct whole
chromosome screening, determine the risk value of chromosomal abnormalities of
each embryo and determine the order of embryo transfer according to the risk
value. For people with clear indications of PGT-A, we suggest that SCM samples be
stored while biopsy samples are collected, especially for the laboratory or biopsy
operator who has just performed biopsy. If there is no result or the result of biopsy
cannot be used, SCM test results could provide remedial measures for the failure of
detection due to sample loss or operation. In addition, for IVF cycles with poor
quality or a small number of embryos, we should minimize the damage of biopsy
operations to embryos and consider the detection of chromosome aneuploidy by
SCM under the premise of full knowledge.
Exogenous contamination of embryos has been a more concerning issue at
present. To improve the accuracy of detection, DNA fragments from embryos
should be identified by differentiated DNA fragment length or linkage analysis in a
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bioinformatics platform. In addition, due to the different fertilization methods of
IVF embryos, researchers have been worried that sperm will interfere with SCM. If
we find a way to eliminate maternal or paternal contamination, it will be supplied to
IVF embryos. We can use this technology to eliminate the problem of chromosome
aneuploidy through non-invasive PGT-A to achieve ideal clinical outcomes for a
wider population.
At the same time, non-invasive PGT detection can try not only for aneuploidy
detection but expand to the comprehensive evaluation on the based on morphology
and take into account the DNA concentration, chimaeric ratio, resolution, consis-
tency with the gold standard and other factors of embryonic SCM. With the accu-
mulation of clinical outcomes, it can also be combined with the clinical data of
patients as an index to predict the clinical outcomes of embryos.
A noninvasive artificial intelligence embryo evaluation model could be
established, which not only provides suggestions for clinicians on the order of
embryo implantation but also provides patients with the most suitable and eco-
nomical detection scheme, ultimately saving time for pregnancy and improving the
overall success rate of IVF-ET.
6. Conclusions
As the findings of non-invasive PGT-A (NIPGT-A) research have been
discussed, and researchers have noticed that the success rate and accuracy of the
test are closely related to the types of culture medium, culturing and methods,
sampling method, detection platform s and gold-standard reference used of detec-
tion. This chapter systematically expounds on how researchers use foetal free DNA
for non-invasive PGT-A detection and thoroughly analyses the factors affecting its
accuracy, possible problems and future application prospects. We hope that it
serves as a good reference for non-invasive PGT-A being widely used in standard-
ized operations before clinical application.
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Acronyms and abbreviations
PGT-A Preimplantation Genetic Testing For Aneuploidy
cfDNA Cell-free DNA
niPGT-A non-invasive PGT-A
IVF-ET In vitro fertilization and embryo transfer
eSET elective single embryo transfer
BCM blastocoel fluid and spent culture medium
SCM spent culture media
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NICS-INST Non-invasive chromosome screening: an improved MALBAC
whole genome amplification (WGA) strategy
PGT-SR Preimplantation Genetic Testing for Structural Rearrangement
WGA whole genome amplification
MDA multiple displacement amplification
MALBAC multiple annealing and looping-based amplification cycles




CNV copy number variations
aCGH array-based comparative genomic hybridization
ICSI Intracytoplasmic sperm injection
PB Polar body
STR short tandem repeat
SNP single nucleotide polymorphism
HSA Human serum albumin
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